- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Saccharomyces boulardii.
Displaying page 1 of 1.
EudraCT Number: 2009-017374-20 | Sponsor Protocol Number: BNI-2009-01 | Start Date*: 2010-04-19 | |||||||||||||||||||||
Sponsor Name:Bernhard-Nocht-Institute for Tropical Medicine | |||||||||||||||||||||||
Full Title: Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea – randomised, double-blind, placebo-controlled trial | |||||||||||||||||||||||
Medical condition: Antibiotic - associated - Diarrhoea (AAD) Clostridium difficile - associated - Diarrhoea (CDAD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003654-33 | Sponsor Protocol Number: FLORAL-Sb185 | Start Date*: 2016-12-14 | |||||||||||
Sponsor Name:BIOCODEX | |||||||||||||
Full Title: Effects of the probiotic Saccharomyces boulardii CNCM I-745 and the antibiotic Amoxicillin on the gut microbiota of healthy volunteers An open-label, randomized, parallel groups, monocentric study | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001426-14 | Sponsor Protocol Number: Preda | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PROVINCIALE DI LECCO | |||||||||||||
Full Title: a probiotic for the prevention of diarrhoea associated with antibiotics | |||||||||||||
Medical condition: Diarrheoa from AAD and CD | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000192-27 | Sponsor Protocol Number: GutHeart1 | Start Date*: 2015-03-19 |
Sponsor Name:Oslo University Hospital | ||
Full Title: GutHeart: Targeting Gut microbiota to treat Heart failure | ||
Medical condition: Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002782-32 | Sponsor Protocol Number: C13006 | Start Date*: 2009-03-02 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative C... | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis Colitis ulcerosa moderada o grave | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) EE (Completed) HU (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) DK (Completed) IS (Completed) PT (Prematurely Ended) BE (Completed) FR (Completed) GB (Completed) BG (Completed) IT (Completed) MT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000482-31 | Sponsor Protocol Number: MLN0002SC-3030 | Start Date*: 2016-01-22 | ||||||||||||||||
Sponsor Name:Takeda Development Centre Europe, Ltd. | ||||||||||||||||||
Full Title: A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn’s Disease | ||||||||||||||||||
Medical condition: Ulcerative Colitis Crohn’s Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) CZ (Completed) NL (Completed) BG (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) SE (Completed) DK (Completed) LT (Completed) ES (Prematurely Ended) HU (Completed) RO (Completed) HR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003985-15 | Sponsor Protocol Number: APD334-301 | Start Date*: 2019-06-21 | ||||||||||||||||
Sponsor Name:Arena Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | ||||||||||||||||||
Medical condition: Ulcerative Colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) BE (Completed) DE (Completed) LV (Completed) AT (Completed) NL (Completed) LT (Completed) PT (Completed) FR (Completed) EE (Completed) HU (Completed) DK (Completed) CZ (Completed) PL (Completed) BG (Completed) ES (Ongoing) HR (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001942-28 | Sponsor Protocol Number: APD334-003 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerativ... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) ES (Completed) DE (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) PL (Completed) BG (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003986-33 | Sponsor Protocol Number: APD334-302 | Start Date*: 2019-07-01 | ||||||||||||||||
Sponsor Name:Arena Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | ||||||||||||||||||
Medical condition: Ulcerative Colitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) FR (Completed) DK (Completed) LT (Completed) BG (Completed) PT (Completed) LV (Prematurely Ended) HU (Completed) PL (Completed) HR (Completed) ES (Ongoing) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000529-31 | Sponsor Protocol Number: 20110232 | Start Date*: 2012-11-09 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease | |||||||||||||
Medical condition: Moderate to severe Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016488-12 | Sponsor Protocol Number: C13011 | Start Date*: 2011-07-12 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease | |||||||||||||
Medical condition: Moderate to Severe Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) BE (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000937-30 | Sponsor Protocol Number: ABX464-101 | Start Date*: 2017-09-29 | |||||||||||
Sponsor Name:ABIVAX | |||||||||||||
Full Title: A Phase IIa study to evaluate the safety and efficacy of ABX464 50 mg once daily versus Placebo in subjects with Moderate to Severe Active Ulcerative Colitis who have failed or are intolerant to im... | |||||||||||||
Medical condition: Moderate to severe Ulcerative Colitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) FR (Completed) DE (Completed) PL (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002784-14 | Sponsor Protocol Number: C13008 | Start Date*: 2009-04-28 | ||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease | ||||||||||||||||||
Medical condition: Ulcerative Colitis and Crohn’s Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: EE (Completed) HU (Completed) AT (Completed) SK (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) FR (Completed) BE (Completed) ES (Completed) MT (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002182-21 | Sponsor Protocol Number: Vedolizumab-2005 | Start Date*: 2017-11-16 | ||||||||||||||||
Sponsor Name:Takeda Development Centre Europe, Ltd. | ||||||||||||||||||
Full Title: A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease. (Long-term Safety With Vedolizumab IV in Pediatric... | ||||||||||||||||||
Medical condition: Ulcerative Colitis or Crohn’s Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DE (Prematurely Ended) BE (Completed) NL (Completed) PL (Trial now transitioned) FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
